The purpose of this study is to test two different treatments, abrocitinib and ritlecitinib, to see if either or both can preserve insulin production in people newly diagnosed with (stage 3) type 1 diabetes.
Thank you for your interest, but this study is recruiting by invitation only.
United States (Nationwide)
Nina Jain
Pediatrics - Children's Research Institute
Clinical or Medical
Interventional
Child and Teen Health
Diabetes
24-3175
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
